Cutibacterium Acnes Postbiotics for Anti-Inflammatory Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-inflammatory treatments for dermatological and gynecological conditions often have side effects and contribute to antibiotic resistance, necessitating the development of alternative products with anti-inflammatory and antimicrobial activity that are safe for prolonged use.
Innovation Solution
A selected bacterial strain of Cutibacterium acnes, deposited as DSM 28251, and its postbiotics or cell wall fragments exhibit anti-inflammatory and antimicrobial properties, promoting fibroblast growth and interfering with pathogen attachment, suitable for topical and systemic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-inflammatory drugs are used to treat inflammation, then inflammation is reduced, but side effects occur and antibiotic resistance increases
Solution Approach 1:
The patent converts the harmful overgrowth of Cutibacterium acnes (which causes acne and inflammation) into a beneficial therapeutic agent. The selected strain produces anti-inflammatory substances and competes with pathogenic bacteria, transforming a harmful microbiota member into a useful treatment for skin infections and inflammation.
Solution Approach 2:
The patent uses a selected strain of Cutibacterium acnes as an intermediary substance that mediates between the host immune system and pathogenic microorganisms. This strain produces metabolic products that modulate inflammation and directly compete with pathogens, serving as a bridge therapy that avoids the harmful effects of conventional antibiotics and steroids.
2Reliability
If steroidal creams are used for topical anti-inflammatory treatment, then skin inflammation is treated, but side effects increase due to abuse or misuse
Solution Approach 1:
The patent employs a biodegradable biological agent (bacterial strain and its metabolic products) that naturally decomposes in the body, eliminating the need for long-term use of persistent synthetic steroids. The therapeutic action is provided by temporary metabolic products that break down after serving their function, avoiding accumulation and long-term side effects.
3Reliability
If antibiotic products are used for treating skin infections, then infections are treated, but resistance to local antibiotic therapy increases
Solution Approach 1:
The patent segments the antimicrobial action into multiple components: the selected C. acnes strain produces various anti-inflammatory and antimicrobial substances, while its cell wall fragments provide structural anti-inflammatory activity. This multi-component approach prevents resistance development by using diverse mechanisms rather than a single antibiotic compound.
Solution Approach 2:
The patent changes the chemical and biological parameters of the treatment by using a live bacterial strain with specific genomic characteristics (selected for producing anti-inflammatory substances) rather than conventional antibiotics. The strain's metabolic profile and cell wall composition provide unique anti-infective properties that are resistant to conventional antibiotic resistance mechanisms.
Data Source
AI summary
The present invention relates to a selected bacterial strain of Cutibacterium acnes and/or a cell wall therefrom or a post-biotic of the strain and to medical or nutritional uses thereof. The invention also concerns with pharmaceutical or nutritional compositions containing the strain, cell wall or postbiotic therefrom for the prevention or treatment of inflammatory diseases such as dermatitis or psoriasis or infections, especially skin or mucosal fungal or bacterial infections.